CHMA - CHMA STOCK NEWS

Chiasma, Inc. (NASDAQ: CHMA) reported a phased launch of MYCAPSSA®, its first oral therapy for acromegaly, achieving $1.1 million in net product revenue for 2020, primarily in Q4. The company secured payor coverage for over 150 million lives and enrolled over 200 patients in a disease state registry. Despite a $19.8 million net loss in Q4 and a total $74.8 million net loss for 2020, cash reserves increased to $135.4 million. Anticipated operating expenses for 2021 range from $80 million to $90 million.

Chiasma, a biopharmaceutical company, will present an overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on demand starting at 7:00 am on March 9, 2021. Chiasma focuses on developing oral therapies to improve treatments for rare chronic diseases. Notably, the company received FDA approval for MYCAPSSA, the first oral somatostatin analog, for acromegaly patients who have tolerated prior injectable treatments. For more details, visit www.chiasma.com.

Chiasma, Inc. (NASDAQ: CHMA) announced a conference call and live audio webcast on March 4, 2021, at 5:00 PM ET, to discuss its financial results for the quarter and year ended December 31, 2020, along with a business update. Domestic participants can join the call at 877-407-4018 or international at 201-689-8471. The conference ID is 13715763. A webcast will be accessible at this link and will be archived on Chiasma’s website.

Chiasma, Inc. (NASDAQ: CHMA) appointed John Doyle as its new Chief Financial Officer effective immediately. Doyle's extensive financial leadership experience includes previous roles at Verastem and SimpliVity. His appointment comes amid the ongoing launch of MYCAPSSA, the first oral therapy for acromegaly. Mark Fitzpatrick, the former CFO, will assist in the transition until June 30, 2021. Doyle expressed enthusiasm for Chiasma's commitment to improving patient lives through MYCAPSSA. With approximately 8,000 adult acromegaly patients in the U.S. relying on injectables, this transition could be pivotal for Chiasma's growth.

Chiasma announced the continued success of MYCAPSSA in the U.S., the first oral treatment for acromegaly, highlighting positive physician, patient, and payer feedback. The company reported expected 2020 net revenues between $0.9 and $1.1 million and anticipates significant growth in 2021, including a planned EMA submission for MYCAPSSA by mid-2021 following promising MPOWERED Phase 3 clinical trial results. Chiasma raised approximately $150 million in 2020, solidifying its financial position for ongoing operations.

Chiasma, a biopharmaceutical company, will present at both the Piper Sandler Healthcare Conference and the Evercore ISI HealthCONx Conference. The Piper Sandler event is on November 23, 2020, at 10:00 am ET, featuring a fireside chat. The Evercore conference will be held on December 3, 2020, at 1:00 pm ET, with a panel discussion on oral therapies. Live webcasts are accessible on Chiasma's website, along with replays available for 90 days. Chiasma focuses on oral treatments for rare diseases and has FDA approval for MYCAPSSA.

On November 30, 2020, Chiasma (NASDAQ: CHMA) will host an expert panel discussing the results of the MPOWERED Phase 3 clinical trial for MYCAPSSA, an oral treatment for acromegaly. Key Opinion Leader Dr. Maria Fleseriu will present topline data and address the unmet medical needs in the condition. The MPOWERED trial, emphasizing non-inferiority to injectable treatments, involved 146 adult patients and aimed to support a potential marketing application in the EU. MYCAPSSA is significant for patients seeking alternatives to painful injections.

Chiasma, Inc. (NASDAQ: CHMA) announced positive top-line results from its global Phase 3 MPOWERED trial for MYCAPSSA (oral octreotide capsules), aimed at treating acromegaly. The trial demonstrated that 91% of patients maintained IGF-1 response over nine months, achieving the primary non-inferiority endpoint compared to injectable therapies. The company plans to submit a marketing application to the European Medicines Agency in mid-2021, bolstering the treatment's potential in the market.

Chiasma (NASDAQ: CHMA), a biopharmaceutical company, announced participation in the Jefferies Virtual London Healthcare Conference from November 17-19, 2020. The company's management will present on November 19 at 2:55 PM ET in a fireside chat format. A live audio webcast of the event will be accessible in the News and Investors section of Chiasma’s website. Notably, Chiasma recently received FDA approval for MYCAPSSA, the first oral therapy for acromegaly, highlighting its commitment to improving treatment options for rare diseases.